Real life single centre experience with tofacitinib: Characteristics of treatment response
Introduction: Tofacitinib was recently approved for juvenile idiopathic arthritis (JIA). To date only limited longitudinal ‚real-life‘ data was reported. We describe our experience including analyses if treatment response had associations to pretreatment or time of start. Methods: We [for full text, please go to the a.m. URL]
Institutions
- Luther University (KR)
- Voestalpine (Brazil) (BR)
- Martin Luther University Halle-Wittenberg (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2024-09-18
- DOI
- https://doi.org/10.3205/24dgrh134
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00